{
    "clinical_study": {
        "@rank": "43739", 
        "acronym": "FIDEL", 
        "arm_group": [
            {
                "arm_group_label": "Human Fibrinogen concentrate", 
                "arm_group_type": "Experimental", 
                "description": "2 vials (200ml) / 3g intravenous"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "2 vials (200ml)"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of the study is to assess the benefits of a therapeutic strategy that associates\n      an early administration of human fibrinogen concentrate in the management of PPH on the\n      reduction of bleeding after the initiation of prostaglandins intravenous infusion, following\n      vaginal delivery."
        }, 
        "brief_title": "Fibrinogen in Haemorrhage of Delivery", 
        "completion_date": {
            "#text": "March 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Post-Partum Hemorrhage", 
        "condition_browse": {
            "mesh_term": [
                "Hemorrhage", 
                "Postpartum Hemorrhage"
            ]
        }, 
        "detailed_description": {
            "textblock": "Randomised, double-blind,multicenter, placebo-controlled study"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Signed and dated informed consent form\n\n          -  Vaginal delivery\n\n          -  PPH requiring IV administration of prostaglandins\n\n          -  At least one available result of Hb level during the third trimester of pregnancy\n\n          -  18-year-old female patients and older\n\n          -  Covered by healthcare insurance in accordance with local requirements\n\n        Exclusion Criteria:\n\n          -  Caesarean section\n\n          -  Haemostatic intervention (as ligation, embolization or hysterectomy) already decided\n             at the time of inclusion\n\n          -  Known placenta praevia or accreta\n\n          -  Hb level < 10g/dl during the third trimester of pregnancy\n\n          -  History of venous or arterial thromboembolic event\n\n          -  Known inherited bleeding or thrombotic disorders\n\n          -  Treatment with low-molecular-weight heparin (LMWH) within 24 hours prior to the\n             inclusion\n\n          -  Treatment with acetylsalicylic acid within 5 days prior to the inclusion\n\n          -  Treatment with vitamin K antagonists within 7 days prior to the inclusion\n\n          -  Administration of fibrinogen concentrate within 48 hours prior to the inclusion\n\n          -  Administration of FFP, platelets units or prohaemostatic drugs, tranexamic acid and\n             rFVIIa or prothrombin complex concentrates (PCC) within 48 hours prior to the\n             inclusion\n\n          -  Administration of RBCs within 3 months prior to the inclusion\n\n          -  Participation in another interventional clinical study within 30 days prior to the\n             inclusion\n\n          -  Previous inclusion/enrolment in the present clinical study\n\n          -  Known history of hypersensitivity or other severe reaction to any component of\n             Clottafact\u00ae or placebo\n\n          -  Minors, majors under guardianship, persons staying in health or social institutes and\n             people deprived of their freedom\n\n          -  Known drug or alcohol abuse\n\n          -  Patients whose use of concomitant medication may interfere with the interpretation of\n             data\n\n          -  Any other current significant medical condition that might interfere with treatment\n             evaluation according to the investigator's judgement\n\n          -  Patients who are unlikely to survive through the treatment period and evaluation\n\n          -  Patients transferred from another service"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "434", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 20, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02155725", 
            "org_study_id": "FIDEL", 
            "secondary_id": "2013-002484-26"
        }, 
        "intervention": [
            {
                "arm_group_label": "Human Fibrinogen concentrate", 
                "description": "Injection as soon as possible and within 30 min following the start of prostaglandin infusion", 
                "intervention_name": "Human Fibrinogen concentrate", 
                "intervention_type": "Drug", 
                "other_name": "Clottafact, LFB"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "As soon as possible and within 30 min following the start of prostaglandin infusion", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug", 
                "other_name": "Placebo"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "PPH", 
            "fibrinogen", 
            "vaginal delivery"
        ], 
        "lastchanged_date": "June 3, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Angers", 
                        "country": "France", 
                        "zip": "49933"
                    }, 
                    "name": "CHU d'Angers"
                }, 
                "investigator": {
                    "last_name": "Sigismond LASOCKI, Dr", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bron", 
                        "country": "France", 
                        "zip": "69500"
                    }, 
                    "name": "H\u00f4pital Femme M\u00e8re Enfant"
                }, 
                "investigator": {
                    "last_name": "Dominique CHASSARD, Pr", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Clamart", 
                        "country": "France", 
                        "zip": "92141"
                    }, 
                    "name": "H\u00f4pital Antoine B\u00e9cl\u00e8re"
                }, 
                "investigator": {
                    "last_name": "Fr\u00e9d\u00e9ric MERCIER, Pr", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Colombes", 
                        "country": "France", 
                        "zip": "92701"
                    }, 
                    "name": "H\u00f4pital Louis Mourier"
                }, 
                "investigator": {
                    "last_name": "Hawa KEITA-MEYER, Pr", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Le Kremlin-bicetre", 
                        "country": "France", 
                        "zip": "94275"
                    }, 
                    "name": "H\u00f4pital Bic\u00eatre"
                }, 
                "investigator": {
                    "last_name": "Toni KFOURY, Dr", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lens", 
                        "country": "France", 
                        "zip": "62307"
                    }, 
                    "name": "Centre Hospitalier de Lens"
                }, 
                "investigator": {
                    "last_name": "Jihad MALLAT, Dr", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lille", 
                        "country": "France", 
                        "zip": "59037"
                    }, 
                    "name": "CHU de Lille, Maternit\u00e9 Jeanne de Flandre"
                }, 
                "investigator": {
                    "last_name": "Julien COROUGE, Dr", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Limoges", 
                        "country": "France", 
                        "zip": "87042"
                    }, 
                    "name": "CHU de Limoges"
                }, 
                "investigator": {
                    "last_name": "Nathalie NATHAN, Pr", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lyon", 
                        "country": "France", 
                        "zip": "69004"
                    }, 
                    "name": "H\u00f4pital de la Croix Rousse"
                }, 
                "investigator": {
                    "last_name": "Fran\u00e7oise BROISIN, Dr", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Montpellier", 
                        "country": "France", 
                        "zip": "34295"
                    }, 
                    "name": "CHRU de Montpellier"
                }, 
                "investigator": {
                    "last_name": "Estelle MORAU, Dr", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nancy", 
                        "country": "France", 
                        "zip": "54042"
                    }, 
                    "name": "Maternit\u00e9 R\u00e9gionale Universitaire de Nancy"
                }, 
                "investigator": {
                    "last_name": "Florence VIAL, Dr", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Paris", 
                        "country": "France", 
                        "zip": "75679"
                    }, 
                    "name": "H\u00f4pital Cochin"
                }, 
                "investigator": {
                    "last_name": "Alexandre MIGNON, Pr", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Paris", 
                        "country": "France", 
                        "zip": "75970"
                    }, 
                    "name": "H\u00f4pital Tenon"
                }, 
                "investigator": {
                    "last_name": "Francis BONNET, Pr", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Paris", 
                        "country": "France", 
                        "zip": "75571"
                    }, 
                    "name": "H\u00f4pital Armand Trousseau"
                }, 
                "investigator": {
                    "last_name": "Agnes RIGOUZZO, Dr", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Reims", 
                        "country": "France", 
                        "zip": "51092"
                    }, 
                    "name": "CHU de Reims, H\u00f4pital Maison Blanche"
                }, 
                "investigator": {
                    "last_name": "Jean-Marc MALINOVSKY, Pr", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Strasbourg", 
                        "country": "France", 
                        "zip": "67200"
                    }, 
                    "name": "H\u00f4pital de Hautepierre"
                }, 
                "investigator": {
                    "last_name": "Pierre DIEMUNSCH, Pr", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Suresnes", 
                        "country": "France", 
                        "zip": "92151"
                    }, 
                    "name": "H\u00f4pital Foch"
                }, 
                "investigator": {
                    "last_name": "Marc FISCHLER, Pr", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Toulouse", 
                        "country": "France", 
                        "zip": "31059"
                    }, 
                    "name": "H\u00f4pital Paul de Viguier - Site Purpan"
                }, 
                "investigator": {
                    "last_name": "Fran\u00e7oise BAYOUMEU, Dr", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tours", 
                        "country": "France", 
                        "zip": "37044"
                    }, 
                    "name": "CHU de Tours"
                }, 
                "investigator": {
                    "last_name": "Jean-Christophe MANGIN, Dr", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Valenciennes", 
                        "country": "France", 
                        "zip": "59300"
                    }, 
                    "name": "CH de Valenciennes"
                }, 
                "investigator": {
                    "last_name": "Laurent CHONOW, Dr", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "2", 
        "official_title": "Study on the Efficacy and Safety of a Therapeutic Strategy of PPH Comparing Early Administration of Human Fibrinogen vs Placebo in Patients Treated With IV Prostaglandins Following Vaginal Delivery", 
        "overall_contact": {
            "email": "anne-sophie.ducloy@chru-lille.fr", 
            "last_name": "Anne-Sophie DUCLOY-BOUTHORS, Dr", 
            "phone": "+33 3 20 44 63 15"
        }, 
        "overall_official": [
            {
                "affiliation": "Maternit\u00e9 Jeanne de Flandre - 59037 LILLE", 
                "last_name": "Anne-Sophie DUCLOY-BOUTHORS, Dr", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "H\u00f4pital Antoine B\u00e9cl\u00e8re - 92140 CLAMART", 
                "last_name": "Fr\u00e9d\u00e9ric MERCIER, Pr", 
                "role": "Study Chair"
            }, 
            {
                "affiliation": "H\u00f4pital Cochin - 75014 PARIS", 
                "last_name": "Alexandre MIGNON, Pr", 
                "role": "Study Chair"
            }, 
            {
                "affiliation": "H\u00f4pital Croix Rousse -69004 LYON", 
                "last_name": "Cyril HUISSOUD, Dr", 
                "role": "Study Chair"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
                "France: Committee for the Protection of Personnes", 
                "France: Conseil National de l'Ordre des M\u00e9decins", 
                "France: French Data Protection Authority"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "February 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Percentage of patients losing at least 4 g/dl of Hb, and/or requiring the transfusion of at least 2 units of packed RBCs within the 48 hours following the administration of IMP.", 
            "safety_issue": "No", 
            "time_frame": "48h following IMP administration"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02155725"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Percentage of patients losing at least 4g/dL and 3g/dL of Hb with regards to the Hb reference level", 
                "measure": "Evolution of haemorrhage", 
                "safety_issue": "No", 
                "time_frame": "48h following IMP administration"
            }, 
            {
                "measure": "Percentage of patients requiring at least one hemostatic intervention", 
                "safety_issue": "No", 
                "time_frame": "48h following IMP administration"
            }, 
            {
                "description": "Length of stay in resuscitation and/or in intensive care unit", 
                "measure": "Maternal morbi-mortality", 
                "safety_issue": "No", 
                "time_frame": "at each follow-up assessment , up to 6 +/- 2 weeks after delivery"
            }, 
            {
                "measure": "Change in plasma fibrinogen level between H0 and Day 2, after early administration", 
                "safety_issue": "No", 
                "time_frame": "48h following IMP administration"
            }, 
            {
                "measure": "Number of patients with at least one AE and/or SAE", 
                "safety_issue": "Yes", 
                "time_frame": "at each follow-up assessment, up to 6 +/- 2 weeks after delivery"
            }, 
            {
                "description": "Percentage of patients losing at least 4g/dL with regards to Hb level measured at inclusion", 
                "measure": "Evolution of haemorrhage", 
                "safety_issue": "No", 
                "time_frame": "48h following IMP administration"
            }, 
            {
                "description": "Percentage of patients requiring the transfusion of at least 2 units of packed RBCs", 
                "measure": "Evolution of haemorrhage", 
                "safety_issue": "No", 
                "time_frame": "48h following IMP administration"
            }, 
            {
                "description": "Number of units of transfused blood products", 
                "measure": "Evolution of haemorrhage", 
                "safety_issue": "No", 
                "time_frame": "48h following IMP administration"
            }, 
            {
                "description": "Total blood loss", 
                "measure": "Evolution of haemorrhage", 
                "safety_issue": "No", 
                "time_frame": "48h following IMP administration"
            }, 
            {
                "description": "SOFA score in women transferred to resuscitation and/or intensive care unit", 
                "measure": "Maternal morbi-mortality", 
                "safety_issue": "No", 
                "time_frame": "at each follow-up assessment, up to 6 +/- 2 weeks after delivery"
            }, 
            {
                "description": "Death during the study", 
                "measure": "Maternal morbi-mortality", 
                "safety_issue": "No", 
                "time_frame": "at each follow-up assessment, up to 6 +/- 2 weeks after delivery"
            }
        ], 
        "source": "Laboratoire fran\u00e7ais de Fractionnement et de Biotechnologies", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Laboratoire fran\u00e7ais de Fractionnement et de Biotechnologies", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}